Seyed Javad Moghaddam, MD, ATSF

Associate Professor
Pulmonary Medicine, UT MD Anderson Cancer Center
Director of Immunology Program, MD Anderson UTHealth Houston Graduate School of Biomedical Sciences

Comparative Effects of Combustible Cigarette versus Electronic Cigarette Exposures on Lung Microenvironment and Microbiome of Kras Mutant Lung Cancer

Dr. Seyed Javad Moghaddam is an Associate Professor (tenured) at the Department of Pulmonary Medicine, UT MD Anderson Cancer Center, and director of the Immunology Graduate Program at MD Anderson UTHealth Houston Graduate School of Biomedical Sciences, Houston, TX. He also serves as a faculty member and lecturer for other training programs such as the CPRIT-CURE Training Program, CPRIT Postdoctoral Fellowship in Cancer Prevention Program, and King Foundation Summer Program.

Dr. Moghaddam has received numerous awards including Lung Cancer Discovery Award (American Lung Association), Research Scholar Award (American Cancer Society), and Cyrus Scholar Award in Basic/Translational Research (Cyrus Family Foundation). He is the 2017 recipient of the American Thoracic Society Early Career Achievement Award in Thoracic Oncology where he currently serves as an executive committee member on its Thoracic Oncology Assembly. Recently, he was elected as a Fellow of the American Thoracic Society for his dedication to the Society and his significant contributions to the fields of pulmonary, critical care, and/or sleep medicine locally, nationally, and internationally.

Overall, his research program is focused on airway inflammation, intrinsic (e.g. oncogene driven) and extrinsic (e.g. smoke or infection induced), and its role in airway epithelial tumorigenesis. His research team has developed and interrogated various human-relevant mouse models that closely emulate the molecular pathobiology of human airway inflammation, COPD, and lung cancer. His group is working on understanding the cell type specific roles of inflammatory signaling pathways in lung carcinogenesis. These studies have the potential to detect and target important pathways in lung tumorigenesis, which could have major impacts on the prevention and treatment of lung cancer. They will also lay the groundwork to develop predictive and prognostic biomarkers to identify responders and non-responders. He has actively published, been well-funded, and trained several postdoctoral fellows, medical students, as well as college, and graduate students in this field.